InflaRx NVMEX:IFRXN 30 Gross Margin % is 0.00% as of Mar. 2026. GuruFocus rates MEX:IFRXN with a GF Score™ of 30/100. The stock has 5 warning signs investors should review. Among 737 Biotechnology companies, InflaRx NV ranks worse than 99.86% on this metric.
The historical rank and industry rank for InflaRx NV's Gross Margin % or its related term are showing as below:
MEX:IFRXN'
s Gross Margin % Range Over the Past 10 Years
Min: -25524.24 Med: -1895.98 Max: -740.58
Current: -25524.24
During the past 11 years, the highestGross Margin % of InflaRx NV was -740.58%. The lowest was -25524.24%. And the median was -1895.98%.
MEX:IFRXN's Gross Margin % is ranked worse than 99.86% of 737
companies
in the Biotechnology industry
Industry Median: 60.92
vs MEX:IFRXN: -25524.24
InflaRx NV had a gross margin of N/A% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
The 5-Year average Growth Rate of Gross Margin for InflaRx NV was 0.00% per year.
InflaRx NV (MEX:IFRXN) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
InflaRx NV had a gross margin of N/A% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
InflaRx NV Gross Margin % Related Terms
InflaRx NV Gross Margin % Historical Data
* Premium members only.
The historical data trend for InflaRx NV's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:IFRXN vs IRD, NAUT, RGNX: Gross Margin % Comparison
For the Biotechnology subindustry, InflaRx NV's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InflaRx NV Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, InflaRx NV's Gross Margin % distribution charts can be found below:
* The bar in red indicates where InflaRx NV's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
InflaRx NV (MEX:IFRXN) has a Gross Margin % of 0.00% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on InflaRx NV and its competitors. According to the industry distribution chart, InflaRx NV ranks #736 out of 737 companies in the Biotechnology industry, placing it in the top 99.9%.
Is InflaRx NV's Gross Margin % too high?
InflaRx NV's current Gross Margin % is 0.00%. Based on the distribution chart, InflaRx NV ranks #736 out of 737 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, InflaRx NV has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does InflaRx NV's Gross Margin % compare to IRD and NAUT?
According to the Biotechnology industry distribution chart, InflaRx NV ranks #736 out of 737 companies for Gross Margin %. This places InflaRx NV in the lower half of its industry. The industry median Gross Margin % is 60.92. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.92, based on 737 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on InflaRx NV and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InflaRx NV's current Gross Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InflaRx NV stock overvalued right now?
InflaRx NV (MEX:IFRXN) has a current Gross Margin % of 0.00%. The current Gross Margin % is 0.00%. InflaRx NV's overall GF Score™ is 30/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For InflaRx NV (MEX:IFRXN), the current Gross Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
30GF Score
Get the complete analysis for MEX:IFRXN
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:IFRXN has been successfully added to your 
